NanoIVD, Inc. Retains Objective Capital Partners to Explore Strategic and Financial Partnerships

Posted January 31, 2019 by OCP | Post a Comment

San Diego, CA and Los Angeles, CA, January 31, 2019 — NanoIVD, Inc., a privately-held company, working on advancing scientific discoveries and understanding of cancer and Alzheimer’s disease for the purpose of diagnosis and treatment, has retained Objective Capital Partners, a middle-market Investment Banking firm located in Southern California and focused on strategic advisory, mergers & acquisitions (M&A), capital financing and valuation services, as their financial advisor.  Objective Capital Partners will seek to identify strategic partnerships and financial investors for NanoIVD to progress the development of their novel work. 


Press News

Objective Capital Partners Advises Everyone Counts on its Sale to Votem

Posted October 29, 2018 by OCP | Post a Comment

Objective Capital Partners, a leading middle market investment banking firm, is pleased to announce that it served as the exclusive advisor to Everyone Counts, a leading online voting and election software company, on its sale to Votem, a leader in blockchain voting systems.


News Announcement

Objective Capital Partners Managing Partner, Trever F. Acers, Named in The San Diego 500 for 2018

Posted October 01, 2018 by OCP | Post a Comment

Objective Capital Partners has consistently been recognized as a leading investment banking firm specializing in M&A, capital raising, strategic partnerships, and valuations. With more than 500 advisory engagements, we are proud to serve the transaction needs of growth stage and mid-sized companies with enterprise values of up to $250 million.



Objective Capital Partners Announced as Finalist for the Valuation Firm of The Year in the 17th Annual M&A Advisor Awards

Posted September 18, 2018 by OCP | Post a Comment

San Diego, September 14, 2018 – Objective Capital Partners, a leading middle-market M&A firm, has been nationally recognized as a Valuation Firm of the Year Award finalist by M&A Advisor for their valuation work in Life Sciences, Healthcare, and Technology.


Press News

Guidance for the Life Science Entrepreneur Looking for Strategic Investments in Their Business: Perfect Your Pitch

Posted August 16, 2018 by OCP | Post a Comment

This past week, David H. Crean, PhD, Managing Director and head of our Life Sciences and Healthcare Practice Group, spent time reviewing the >400 life science opportunities that were presented to him and our investment banking firm in 2017 in which entrepreneurs and business owners were looking for either capital financing, sell-side M&A, strategic advisory services or partnering/ licensing. Nearly invariably, each investment pitch lacked the complete and necessary material to tell the comprehensive story that would be compelling for an investor to write a check. These entrepreneurs are very smart and passionate about their mission but need to recognize and think like investors or strategic buyers. Investors see and hear many investment opportunities and you need to be differentiated and stand out from the masses.


Capital Raise & Financing, Sell-Side M&A, Strategic Advisory, Life Sciences, Healthcare, Blog Article

How To Look Beyond the Obvious Acquirer for Your Business

Posted July 19, 2018 by OCP | Post a Comment

A wise advisor once said, “Obvious buyers are obvious”. This truism serves as a recommendation to sellers to seek beyond the obvious buyers when constructing a list of potential acquirers

Obvious buyers typically identified include a mix of direct competitors and the large players that dominate the sector. Many investment banks often provide sellers with a list of the 25 or so obvious buyers, resulting in the seller feeling a false sense of comfort because all the names of the potential acquirers that they are familiar with are on the list. And, while many of these companies may represent high-fit potential acquirers, the seller is missing out on engaging with a large number of less obvious, high-fit potential acquirers. These acquirers have a strong strategic rationale to acquire and a resulting high willingness to pay a premium purchase price.


Sell-Side M&A, Blog Article, Life Sciences, Healthcare, Technology, Business Services, Consumer, Strategic Advisory

How Family Offices Should Approach Investment in the Life Sciences and Healthcare Industry

Posted June 14, 2018 by OCP | Post a Comment

The fundraising landscape for healthcare and life science companies has changed dramatically over the past several years. Entrepreneurs and business owners in these industries need to look toward emerging categories of investors to provide the funding that was historically serviced by venture capital firms (VC’s). Corporate venture funds, angels and angel networks, government agencies, and foundations are all actively investing in these sectors and represent newer, non-traditional avenues for raising capital. However, the latest growing trend is the participation of family offices.


Life Sciences, Healthcare, Blog Article, Buy-Side M&A

OCP Is Leading Growth in the San Diego Life Science Community

Posted June 04, 2018 by OCP | Post a Comment

"Working with life science companies is not like serving other industries. There are myriad legal and financial eccentricities - accounting for multiple financing sources makes accounting especially complex, for instances and protecting intellectual property is key. Early-stage companies may need their hand held as they focus on the science and outsource everything else." San Diego Business Journal


Life Sciences, Healthcare, Capital Raise & Financing, Business Valuation, Strategic Advisory, Press News

The Difference Between Strategic & Financial Acquirers

Posted June 01, 2018 by OCP | Post a Comment

When owners decide to sell their company, one of the first things they consider is building a list of high-fit potential acquirers for the business. With private equity (financial) acquirers becoming so abundant in the last 10 years (over 2,500 in North America), the list of potential acquirers to approach in the sale process is likely to consist of both strategic and financial acquirers.


Sell-Side M&A, Life Sciences, Healthcare, Technology, Business Services, Consumer, Blog Article

Objective Capital Partners Welcomes Matt Ramirez as Associate

Posted May 10, 2018 by OCP | Post a Comment

We are excited to announce the addition of experienced finance professional, Matt Ramirez, to the firm. Matt brings with him a great depth of finance experience having served previously as a Senior Associate with Ernst & Young's Assurance Services Practice where he led teams in the execution of public and private company financial statement audits.


Press News

This article is provided for informational purposes only and does not constitute an offer, invitation or recommendation to buy, sell, subscribe for or issue any securities. While the information provided herein is believed to be accurate and reliable, Objective Capital Partners and BA Securities, LLC makes no representations or warranties, expressed or implied, as to the accuracy or completeness of such information. It should not be construed as investment, legal, or tax advice and may not be reproduced or distributed to any person.

Our Services

Learn about our services and how we can help you sell your business successfully.


Contact Us

San Diego Office:
3636 Nobel Dr., Suite 160
San Diego, CA 92122

Los Angeles Office:
10100 Santa Monica Blvd., Suite 300
Los Angeles, CA 90067

Trever Acers
Managing Director
858.663.8662 telephone

Channing Hamlet
Managing Director
858.342.4939 telephone

David H. Crean, Ph.D.
Managing Director
858.461.9490 telephone

Jack J. Florio
Managing Director
858.864.4339 telephone